Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanhuangwuji powder is a traditional Chinese medicine formulation used as an adjunct therapy in the management of rheumatoid arthritis (RA), particularly when complicated by peptic ulcer. It is administered orally and has been studied in combination with anti-rheumatic drugs (such as celecoxib, methotrexate, and esomeprazole) and ginger-partitioned acupoint stimulation at zusanli (ST 36). Clinical studies suggest that this combination leads to greater improvements in RA symptoms, laboratory outcomes, gastrointestinal symptom scores, and peptic ulcer healing rates compared to standard anti-rheumatic drug therapy alone or with ginger-partitioned stimulation. The precise mechanism of action for Sanhuangwuji powder is not clearly defined in the available literature; it likely acts through multiple herbal constituents with potential anti-inflammatory and mucosal protective effects[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanhuangwuji powder.